News | November 13, 2023
Vaishali Pharma posts Q2 FY24 PAT at Rs. 1.70 Cr
he company posted total income during Q2 FY24 at Rs. 12.86 crore
he company posted total income during Q2 FY24 at Rs. 12.86 crore
European operations' revenue grew 58.4% to Rs 599.7 crore
US business grew by +12.8% YoY
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
General Medicine grows 5% and Vaccines 10% led by Shingrix
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Total transaction value of the divestment is Rs. 3,660 million
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
Subscribe To Our Newsletter & Stay Updated
